On May 2, 2022 Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the Company’s HPN328, a DLL3 targeting TriTAC, clinical development program (Press release, Harpoon Therapeutics, MAY 2, 2022, View Source [SID1234613321]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to enter into this clinical supply agreement with Roche as it enables us to investigate the impact of HPN328 on solid tumors in combination with atezolizumab and provide further insight into the capabilities of our TriTAC technology platform," stated Julie Eastland, President and CEO, Harpoon Therapeutics. "We are pleased with the compelling profile emerging in our monotherapy study and we plan to initiate combination trials in multiple lines of therapy for patients with small cell lung cancer, a disease with unmet medical need."

Under this agreement, Harpoon is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab.

About HPN328

HPN328 is a DLL3 targeting TriTAC being studied as a single agent in an ongoing clinical trial for patients with small cell lung cancer, neuroendocrine and other DLL3-associated tumors. The Phase 1/2 trial is an open-label study of HPN328 to assess the safety, tolerability and pharmacokinetics in patients with advanced cancers associated with expression of DLL3. HPN328 is being administered in fixed and step dosing to patients once weekly by intravenous infusion with dose escalation until a therapeutic dose level has been achieved. The primary outcome measure will be safety and tolerability, and to determine a dose for Phase 2.

On May 2, 2022 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, reported that the company will release its 2022 first quarter financial results after the market closes on Monday, May 16, 2022 (Press release, CohBar, MAY 2, 2022, View Source [SID1234613320]). Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the Conference Call:

Webcast

– A simultaneous webcast of the call will be accessible via the Investors section of the CohBar website at www.cohbar.com.

For individuals participating in the Investor Call or webcast, please call or login to the conference audio approximately 10 minutes prior to its start.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on May 16, 2022, through 11:59 p.m. Eastern Time on June 6, 2022. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13728737. The audio recording will also be available at www.cohbar.com during the same period.

On May 2, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported plans to release its financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 following the close of financial markets (Press release, Akebia, MAY 2, 2022, View Source [SID1234613319]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Akebia will host a conference call Monday, May 9, 2022 at 4:30 p.m. ET to discuss its financial results and provide a general business update. To listen to the conference call on May 9th, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 1273066. The call will also be webcast LIVE and can be accessed via the Investors section of Akebia’s website at View Source

A replay of the conference call will be available two hours after the completion of the call through May 15, 2022. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 1273066. An online archive of the conference call can be accessed via the Investors section of Akebia’s website at View Source

On May 2, 2022 aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, reported that it will report first quarter 2022 financial results and provide a corporate update after the market close on Monday, May 9, 2022 (Press release, aTyr Pharma, MAY 2, 2022, https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-webcast-conference-call-reporting-first-quarter-2022 [SID1234613318]). Management will host a conference call and webcast to review the results and provide an operational update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 2, 2022 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, MAY 2, 2022, View Source [SID1234613317]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022

Title: Arrowhead’s Approach to Oligonucleotide Scale-Up Manufacturing
Presenter: Michael Lawler, Director, Chemistry, Arrowhead Pharmaceuticals

2022 American Thoracic Society (ATS) International Conference – May 13-18, 2022

Title: Silencing RAGE Expression with a Lung-Targeted RNAi Trigger Delivery Platform Suppresses Pulmonary Allergic Inflammation
Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals

Title: Silencing Muc5ac Expression with a Lung-Targeted RNAi Trigger Prevents Allergen-Induced Mucoobstruction and Airway Hyperresponsiveness
Presenter: David Kasahara, Senior Scientist III, Biology, Arrowhead Pharmaceuticals

BofA Securities 2022 Healthcare Conference – May 12, 2022, 1:40 p.m. ET

Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals

2022 RBC Capital Markets Global Healthcare Conference – May 17, 2022, 4:35 p.m. ET

Type: Fireside chat presentation
Presenter: Christopher Anzalone, President and CEO, Arrowhead Pharmaceuticals

UBS Global Healthcare Conference 2022 – May 25, 2022, 12:15 p.m. ET

Type: Fireside chat presentation
Presenter: Vincent Anzalone, Vice President Finance and Investor Relations, Arrowhead Pharmaceuticals

A copy of the presentation materials and webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.